Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Nautilus Biotechnology (NAUT) Leases (2020 - 2026)

Nautilus Biotechnology has reported Leases over the past 7 years, most recently at $26.6 million for Q1 2026.

  • Quarterly results put Leases at $26.6 million for Q1 2026, down 1.72% from a year ago — trailing twelve months through Mar 2026 was $26.6 million (down 1.72% YoY), and the annual figure for FY2025 was $27.8 million, down 1.71%.
  • Leases reached $26.6 million in Q1 2026 per NAUT's latest filing, down from $27.8 million in the prior quarter.
  • Across five years, Leases topped out at $35.7 million in Q1 2023 and bottomed at $24.7 million in Q3 2025.
  • Median Leases over the past 5 years was $28.9 million (2022), compared with a mean of $29.5 million.
  • The largest annual shift saw Leases surged 3318.36% in 2022 before it fell 15.83% in 2025.
  • Over 5 years, Leases stood at $28.9 million in 2022, then rose by 13.05% to $32.6 million in 2023, then decreased by 13.42% to $28.3 million in 2024, then fell by 1.71% to $27.8 million in 2025, then fell by 4.11% to $26.6 million in 2026.
  • Business Quant data shows Leases for NAUT at $26.6 million in Q1 2026, $27.8 million in Q4 2025, and $24.7 million in Q3 2025.